Compare · KRSA vs NVS
KRSA vs NVS
Side-by-side comparison of Korsana Biosciences Inc. (KRSA) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KRSA and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $296.16B, about 195.5x KRSA ($1.52B).
- KRSA has been more active in the news (12 items in the past 4 weeks vs 5 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 1 for KRSA).
- Company
- Korsana Biosciences Inc.
- Novartis AG
- Price
- -
- -
- Market cap
- $1.52B
- $296.16B
- 1M return
- -
- +5.95%
- 1Y return
- -
- +24.30%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 12
- 5
- Recent ratings
- 1
- 25
Korsana Biosciences Inc.
Korsana Biosciences is committed to building best-in-class therapeutics with the goal of reducing the burden of neurodegenerative diseases for patients and caregivers. The Company's lead program, KRSA-028, is a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer's disease. KRSA-028 leverages Therapeutic Targeting (THETA), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, Korsana is advancing a pipeline of innovative therapies for neurodegenerative diseases.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest KRSA
- Amendment: SEC Form SCHEDULE 13G/A filed by Korsana Biosciences Inc.
- SEC Form SCHEDULE 13G filed by Korsana Biosciences Inc.
- SEC Form SCHEDULE 13G filed by Korsana Biosciences Inc.
- SEC Form SCHEDULE 13G filed by Korsana Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Korsana Biosciences Inc.
- Wells Fargo initiated coverage on Korsana Biosciences with a new price target
- SEC Form SCHEDULE 13G filed by Korsana Biosciences Inc.
- SEC Form S-8 filed by Korsana Biosciences Inc.
- SEC Form 10-Q filed by Korsana Biosciences Inc.
- Korsana Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank